Jyong Biotech Ltd. (MENS)
| Market Cap | 303.76M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.02M |
| Shares Out | 76.90M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,874,521 |
| Open | 4.330 |
| Previous Close | 4.220 |
| Day's Range | 3.900 - 5.350 |
| 52-Week Range | 2.601 - 67.000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 24, 2026 |
About MENS
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan. [Read more]
News
Jyong Biotech Responds to Share Price and Volume Movement
New Taipei City, Taiwan, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”) notes the recent fluctuation in its share price and the increased tradin...
Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry
New Taipei City, Taiwan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to dev...
Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs
New Taipei City, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to dev...
Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes
New Taipei City, Taiwan, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to dev...
Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards
New Taipei City, Taiwan, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd.
Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei
New Taipei City, Taiwan, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to deve...
Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention
New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd.
Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)
New Taipei City, Taiwan, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to devel...
Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks Remain
Jyong Biotech develops botanical drugs for urinary disorders. Their lead asset is clearly MCS‑2, which is currently restarting Phase 3 trials after a previous FDA setback. Their pipeline targets large...
Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention
New Taipei City, Taiwan, July 22, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to devel...
U.S. IPO Weekly Recap: Sizable Precision Medicine And Insurance IPOs Raise A Combined $902 Million
A handful of IPOs and blank checks priced in the short holiday week, led by two sizable issuers. Two smaller IPOs also priced this past week. One IPO is currently scheduled to list in the week ahead, ...
Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering
New Taipei City, Taiwan, June 18, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”), a science-driven biotechnology company based in Taiwan committed to developing and commerc...
Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering
New Taipei City, Taiwan, June 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (the “Company”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innova...
Jyong Biotech Seeks US IPO On Thin Capitalization And Uphill Regulatory Battle
Jyong Biotech Ltd. aims to raise $18.8 million in an IPO, but faces significant risks including high debt, legal issues, and FDA approval challenges. The lead drug candidate, MCS-2, has completed Phas...
Jyong Biotech Ltd. Begins U.S. IPO Rollout
Jyong Biotech Ltd. is seeking to raise $40.25 million in an IPO to develop plant-based treatments for urinary system diseases. The company's lead candidate, MCS-2, has completed four phase III trials,...
Urinary disease biotech Jyong Biotech files for a $40 million US IPO
Jyong Biotech, a commercial-stage Taiwanese biotech developing therapies for urinary diseases, filed on Thursday with the SEC to raise up to $40 million in an initial public offering.
Jyong Biotech IPO Registration Document (F-1)
Jyong Biotech has filed to go public with an IPO on the NASDAQ.